nach oben

European Journal of Epidemiology

Erschienen in:

24.03.2017 | COMMENTARY

Concerns about the long-term safety of live kidney donors are justified

verfasst von: Abimereki D. Muzaale, Allan B. Massie, Dorry L. Segev

Erschienen in: European Journal of Epidemiology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Excerpt

Healthy live kidney donors lose approximately 50% of their nephron mass with nephrectomy [1]. Within the first post-donation year, the remaining kidney partially compensates for this loss by means of hyperfiltration, a homeostatic mechanism by which the remnant functional units of the kidney increase in volume and capacity in an attempt to match demand [2]. For this reason, the residual kidney function (glomerular filtration rate, GFR) is typically only 20–45% lower than it was before nephrectomy [3]. …

Ratner LE, Ciseck LJ, Moore RG, Cigarroa FG, Kaufman HS, Kavoussi LR. Laparoscopic live donor nephrectomy. Transplantation. 1995;60(9):1047–9.PubMed

Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. J Am Soc Nephrol JASN. 2001;12(6):1315–25.PubMed

Kasiske BL, Anderson-Haag T, Israni AK, Kalil RS, Kimmel PL, Kraus ES, et al. A prospective controlled study of living kidney donors: three-year follow-up. Am J Kidney Dis. 2015;66(1):114–24.CrossRefPubMedPubMedCentral

Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;311(24):2518–31.CrossRefPubMedPubMedCentral

Poggio ED, Braun WE, Davis C. The science of Stewardship: due diligence for kidney donors and kidney function in living kidney donation–evaluation, determinants, and implications for outcomes. Clin J Am Soc Nephrol CJASN. 2009;4(10):1677–84.CrossRefPubMed

Fehrman-Ekholm I, Norden G, Lennerling A, Rizell M, Mjornstedt L, Wramner L, et al. Incidence of end-stage renal disease among live kidney donors. Transplantation. 2006;82(12):1646–8.CrossRefPubMed

Ibrahim HN, Foley R, Tan L, Rogers T, Bailey RF, Guo H, et al. Long-term consequences of kidney donation. N Engl J Med. 2009;360(5):459–69.CrossRefPubMedPubMedCentral

Cherikh WS, Young CJ, Kramer BF, Taranto SE, Randall HB, Fan PY. Ethnic and gender related differences in the risk of end-stage renal disease after living kidney donation. Am J Transpl. 2011;11(8):1650–5.CrossRef

Mjoen G, Hallan S, Hartmann A, Foss A, Midtvedt K, Oyen O, et al. Long-term risks for kidney donors. Kidney Int. 2014;86(1):162–7.CrossRefPubMed

10.

Muzaale AD, Massie AB, Wang MC, Montgomery RA, McBride MA, Wainright JL, et al. Risk of end-stage renal disease following live kidney donation. JAMA. 2014;311(6):579–86.CrossRefPubMedPubMedCentral

11.

Boudville N, Garg AX. End-stage renal disease in living kidney donors. Kidney Int. 2014;86(1):20–2.CrossRefPubMed

12.

Gill JS, Tonelli M. Understanding rare adverse outcomes following living kidney donation. JAMA. 2014;311(6):577–9.CrossRefPubMed

13.

Kiberd B, Tennankore K. Kidney donation and risk of ESRD. JAMA. 2014;312(1):93.CrossRefPubMed

14.

Matas AJ, Wadstrom J, Ibrahim HN. Kidney donation and risk of ESRD. JAMA. 2014;312(1):92–3.CrossRefPubMed

15.

Niemi M, Mandelbrot DA. Kidney donation and risk of ESRD. JAMA. 2014;312(1):92.CrossRefPubMed

16.

Freedman BI, Spray BJ, Tuttle AB, Buckalew VM Jr. The familial risk of end-stage renal disease in African Americans. Am J Kidney Dis. 1993;21(4):387–93.CrossRefPubMed

17.

Spray BJ, Atassi NG, Tuttle AB, Freedman BI. Familial risk, age at onset, and cause of end-stage renal disease in white Americans. J Am Soc Nephrol JASN. 1995;5(10):1806–10.PubMed

18.

Delmonico F. Council of the transplantation S. A Report of the Amsterdam Forum On the Care of the Live Kidney Donor: Data and Medical Guidelines. Transplantation. 2005;79(6 Suppl):53–66.

19.

Janki S, Steyerberg EW, Hofman A, JN IJ. Live kidney donation: are concerns about long-term safety justified?—a methodological review. Eur J Epidemiol. 2016. doi:10.1007/s10654-016-0168-0.

20.

Matas AJ, Hays RE, Ibrahim HN. Long-term non-end-stage renal disease risks after living kidney donation. Am J Transpl. 2016. doi:10.1111/ajt.14011.

21.

Segev DL, Muzaale AD, Caffo BS, Mehta SH, Singer AL, Taranto SE, et al. Perioperative mortality and long-term survival following live kidney donation. JAMA. 2010;303(10):959–66.CrossRefPubMed

22.

Garg AX, Meirambayeva A, Huang A, Kim J, Prasad GV, Knoll G, et al. Cardiovascular disease in kidney donors: matched cohort study. BMJ. 2012;344:e1203.CrossRefPubMedPubMedCentral

23.

Mjoen G, Reisaeter A, Hallan S, Line PD, Hartmann A, Midtvedt K, et al. Overall and cardiovascular mortality in Norwegian kidney donors compared to the background population. Nephrol Dial Transpl. 2012;27(1):443–7.CrossRef

24.

Garg AX, Nevis IF, McArthur E, Sontrop JM, Koval JJ, Lam NN, et al. Gestational hypertension and preeclampsia in living kidney donors. N Engl J Med. 2015;372(2):124–33.CrossRefPubMed

25.

Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108(17):2154–69.CrossRefPubMed

26.

Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015;3(7):514–25.CrossRefPubMedPubMedCentral

27.

Vikse BE, Irgens LM, Leivestad T, Skjaerven R, Iversen BM. Preeclampsia and the risk of end-stage renal disease. N Engl J Med. 2008;359(8):800–9.CrossRefPubMed

28.

Vikse BE, Hallan S, Bostad L, Leivestad T, Iversen BM. Previous preeclampsia and risk for progression of biopsy-verified kidney disease to end-stage renal disease. Nephrol Dial Transpl. 2010;25(10):3289–96.CrossRef

29.

Delgado-Rodriguez M, Llorca J. Bias. J Epidemiol Commun Health. 2004;58(8):635–41.CrossRef

Titel: Concerns about the long-term safety of live kidney donors are justified
verfasst von: Abimereki D. Muzaale
Allan B. Massie
Dorry L. Segev
Publikationsdatum: 24.03.2017
Verlag: Springer Netherlands
Erschienen in: European Journal of Epidemiology / Ausgabe 2/2017
Print ISSN: 0393-2990
Elektronische ISSN: 1573-7284
DOI: https://doi.org/10.1007/s10654-017-0241-3

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Concerns about the long-term safety of live kidney donors are justified

Excerpt

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Genetic determinants of serum vitamin B12 and their relation to body mass index

Human chorionic gonadotropin (hCG) concentrations during the late first trimester are associated with fetal growth in a fetal sex-specific manner

The prevalence of multiple non-communicable diseases among middle-aged and elderly people: the Shanghai Changfeng Study

The methodological ‘revolution’: caution accepted

Clinical epidemiology: A daydream?

The LIFE Child study: a population-based perinatal and pediatric cohort in Germany